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Purpose: In-stent restenosis has beendecreasing through the introductionof drug-eluting stents (DES). On
the other hand, adverse events such as very late stent thrombosis (VLST) and late catch-up phenomenon
can occur especially with sirolimus-eluting stents (SES, ﬁrst-generation DES) in long-term follow-up.
However, the precise mechanisms underlying VLST have not been well investigated in vivo.
Methods and results: From 2004 to 2010, 2034 SES were implanted in 1656 patients and caused eight
VLST (0.48% per patient) at Fukuoka Tokushukai Medical Center. Of these, serial intravascular ultrasound
(IVUS) images (post-stent implantation and at the time of VLST onset) were obtained from three patients
with VLST. Comparing them with eight control patients with SES implanted, the vascular reactivity of
VLST patients was analyzed. Eight VLST happened 50±15 months after stent implantation and three of
the eight patients with VLST had not taken aspirin daily. There were no differences in minimum stent
area, maximum external elastic membrane (EEM) area, and stent edge (distal and proximal) EEM area
in post-procedural IVUS images. Compared with the control group patients, EEM area (10.6±3.4mm2
2vs. 1.7±1.9mm , p=0.01) and vessel expansion ratio (185.6±40.3% vs. 112.0±12.1%, p=0.01) were
signiﬁcantly greater in the VLST group based on the greater peri-stent plaque expansion (262.1±72.8%
vs. 118.7±21.2%, p=0.01).
Conclusion: Our serial IVUS study showed that the vascular positive remodeling after SES implantation is
one of the most probable morphological mechanisms for VLST development.
© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.In-stent restenosis has decreased with the use of drug-eluting
tents (DES). However, it became clear that some problems had
ccurred with ﬁrst-generation DES in long-term follow-up such as
ery late stent thrombosis (VLST) and late catch-up phenomenon
1]. VLST is one of the most devastating events of DES, and VLST
ore often occurred especially with sirolimus-eluting stents (SES;
ypherTM or Cypher SelectTM or Cypher Select PlusTM, Cordis,
∗ Corresponding author at: 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan.
el.: +81 96 373 5175; fax: +81 96 362 3256.
E-mail address: tsujita@kumamoto-u.ac.jp (K. Tsujita).
ttp://dx.doi.org/10.1016/j.jjcc.2014.02.008
914-5087/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reJohnson & Johnson, Warren, NJ, USA). In Japan, VLST after SES
implantation occurred at a rate of 0.26%/y without attenuation up
to 5-year follow-up [2]. Different from other DES, previous stud-
ies demonstrated that SES-implanted coronary arteries had more
positive remodeling because of inﬂammation by stent polymer and
drug and that SES had often beenmalapposed [3,4]. However, there
were few reports that delineated precise vessel response after SES
implantation using serial intravascular imaging tools performed
both at stent implantation and at the onset of VLST.
Intravascular ultrasound (IVUS) provides real-time, in vivo,
cross-sectional imaging of whole coronary arterial wall struc-
ture before and after stent implantation and at follow-up [5,6].
served.
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specially in Japan, IVUS-guided coronary intervention has been
idely distributed in real-world clinical practice, even during
mergency procedures such as primary intervention for VLST.
herefore, the aim of the present study was to use IVUS images to
lucidate vessel response of SES-implanted segments as one of the
orphological mechanisms underlying post-SES VLST.
ethods
tudy population and patient demographic data
From August 2004 to January 2010, 2034 SES were implanted
n 1656 patients and eight VLST occurred at Fukuoka Tokushukai
edical Center (0.48% per patient, Table 1). In all the eight patients,
LST developed as an acute coronary syndrome and was diagnosed
s VLST by angiography. Based on the Academic Research Con-
ortium (ARC) deﬁnition, all VLST patients were thus classiﬁed as
aving deﬁnite stent thrombosis: ‘symptoms suggestive of an acute
oronary syndrome and angiographic or pathologic conﬁrmation of
tent thrombosis, occurring over 12 months after stent implanta-
ion [7].’ Serial IVUS images (post-stent implantation and at the
ime of VLST onset) were obtained from three of these eight VLST
atients. The remaining ﬁve VLST patients were excluded from this
tudy by non-enforceable IVUS image acquisition owing to hemo-
ynamic instability, incomplete imaging of stented lesion due to
nreliable pullback, and unacceptable IVUS image quality. Non-
LST-experiencedSES-implantedpatientswith serial IVUS imaging
ere extracted from our hospital database as the control group.
omparing IVUS images from the three VLST patients with eight
ontrol IVUS images which were taken post-stent implantation
nd at follow-up angiography routinely performed, morphological
essel response of SES-implanted segment was analyzed precisely.
hese eight control patients were monitored prospectively with
ocumentation of the absence of any clinical adverse event dur-
ng observation period and were ﬁnally selected as IVUS controls.
his study was approved by the institutional review boards of the
nstitutions in which the procedures were performed, and written
nformed consent was obtained from all patients.
Patient demographic data were conﬁrmed by hospital
hart review. Coronary risk factors included diabetes mellitus
diet-controlled, oral agent, or insulin-treated), hypertension
medication-treated only), dyslipidemia (medication-treated or
ow-density lipoprotein >140mg/dL), cigarette smoking, and
amily history of coronary artery disease. Drug adherence to
ntiplatelet agents, which was recognized as one of the most
mportant risk factors for VLST, was examined in detail.
VUS image acquisition and analysis
IVUS images were acquired after intracoronary administra-
ion of nitrates using a commercially-available IVUS catheter
EagleEyeTM, Volcano Corp., Rancho Cordova, CA, USA; View ItTM,
erumo Corp., Tokyo, Japan; Atlantis SR Pro2TM, Boston Scien-
iﬁc Corp., Natick, MA, USA). The selection of IVUS system was
eft to the discretion of the interventional cardiologists. At the
ost-stenting IVUS image acquisition, the catheter was advanced
eyond the implanted stent, and was withdrawn with a motor-
zed catheter pullback system to the extent possible. When VLST
ccurred, the catheter was advanced beyond the thrombosed stent
fter thrombectomy or small-size balloon angioplasty, and imag-
ng was performed with a manual careful pullback as slowly as
ossible to the extent that the hemodynamic state remained sta-
le. IVUS imageswere recorded continuously on CD-R or DVD-R for
ater ofﬂineanalysis.Qualitative andquantitative IVUSanalysiswas
erformed by independent experienced observers (K.Y. and K.T.) Ta
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ccording to the criteria of American College of Cardiology Clinical
xpert Consensus Document on Standards for Acquisition, Mea-
urement and Reporting of Intravascular Ultrasound Studies, and
he consensus interpretation was included in the analysis [8]. With
lanimetry software (EchoPlaqueTM, INDEC Systems, Inc., Moun-
ain View, CA, USA), quantitative IVUS analysis was performed at
heproximal anddistal reference segments to includeexternal elas-
ic membrane (EEM), stent, lumen, peri-stent plaque and media
P&M, EEM minus stent), and intimal hyperplasia (stent minus
umen) cross-sectional area (CSA). Corresponding images of post-
tenting and at-VLST-onset IVUS examinations were identiﬁed by
he ﬁduciary landmarks such as side branches, calciﬁcation, and
tent edges.
Regarding the vessel response, EEM and peri-stent P&M
ere calculated from the differences between post-stenting and
t-VLST-onset IVUS values. Vessel expansion was deﬁned as
ercentage change of EEM area [EEM at follow-up (or at-VLST-
nset)/EEM at index procedure]. Peri-stent plaque expansion was
eﬁnedaspercent changeofperi-stentP&Marea [P&Mat follow-up
or at-VLST-onset)/P&M at index procedure].
tatistical analysis
Statistical analysis was performed with StatView 5.0 (SAS Insti-
ute, Inc., Cary, NC, USA). Continuous variables (mean±1SD) were
ompared with unpaired Student t test or Mann–Whitney U test
s appropriate according to data distribution. Categorical vari-
bles (frequencies)were comparedwith chi-square statistics or the
isher exact test. A p-value <0.05 was considered signiﬁcant.
esultsLST onset and clinical demographics
Clinical background of all eight VLST patients is shown in
able 1. Our present analysis showed that VLST continued to
able 2
linical characteristics between patients with and without very late stent thrombosis.
VLST Group
Age, years 63.3±4
Male sex 2 (67%
Diabetes mellitus 0 (0%)
Hypertension 3 (100
Dyslipidemia 3 (100
Current smoking 1 (33%
Stable angina 2 (67%
Unstable angina 1 (33%
Multivessel disease 3 (100
Left ventricular ejection fraction (%) 58.1±6
SES diameter (mm) 2.67±
SES length (mm) 21.3±5
Follow-up duration (months) 49.7±2
Hemoglobin A1c (%) 5.47±
Lipid proﬁle
Total cholesterol (mg/dL) 166.3±1
Triglyceride (mg/dL) 113.3±3
Low-density lipoprotein cholesterol (mg/dL) 91.0±1
High-density lipoprotein cholesterol (mg/dL0 48.3±1
B-type natriuretic peptide (pg/mL) 54.2±3
Creatinine (mg/dL) 0.75±
Estimated glomerular ﬁltration rate (mL/min/1.73m2) 80.6±2
High-sensitivity C-reactive protein (mg/dL) 0.69±
White blood cell (/L) 10,667±20
Neutrophil (/L) 6685±23
Lymphocyte (/L) 3294±23
Eosinocyte (/L) 99±88
ata are presented as mean±1SD or number (%).
LST, very late stent thrombosis; SES, sirolimus-eluting stent.diology 64 (2014) 279–284 281
occur constantly up to 6 years after SES implantation without
attenuation. Regarding antiplatelet therapy, three patients had
not taken the aspirin daily. In terms of mechanical disturbance
of implanted stents, two patients had stent fracture documented
by angiography or IVUS. In patients No. 5, No. 6, and No. 7, both
post-stenting and at-VLST-onset IVUS images were obtained.
Baseline clinical characteristics were similar in patients with
VLST and controls (Table 2). The situation of implanted SES (clinical
presentation of acute coronary syndrome) and the other coronary
risk factors (dyslipidemia, diabetes mellitus, hypertension, chronic
kidney disease, and current smoking) were comparable between
the groups. The stent length was similar in the two groups. Because
of the blood sampling data collected during the acute phase in the
VLST group, white blood cell count was signiﬁcantly increased in
the VLST group than in the control group.
IVUS ﬁndings
Acquired stent malapposition was more common in the VLST
group than in the control group (62.5% vs. 12.5%, p=0.04). Quan-
titative IVUS ﬁndings are summarized in Table 3. There were no
differences in post-procedural IVUS images between the VLST and
control groups. In follow-up IVUS images, lumen area was smaller
in the VLST group than in the control group at maximal EEM area
site and at minimal stent area site (2.8±2.1mm2 vs. 7.1±3.1mm2,
p=0.04; 3.0±0.7mm2 vs. 5.9±2.8mm2, p=0.07, respectively),
probably because it was impossible to distinguish thrombus
and neointima. Considering the mechanism of vessel expansion,
peri-stent P&M area was signiﬁcantly greater in the VLST group
than in the control group (17.8±2.7mm2 vs. 10.8±3.2mm2,
p=0.03). The comparison of vessel responses is summarized in
Table 4. Vessel expansion ratio was signiﬁcantly more acceler-
ated in the VLST group than in the control group at stent edge
(distal site 167.7±32.1% vs. 101.5±15.8%, p=0.01, proximal site
173±34.2% vs. 111.7±23.0%, p=0.04) and at maximum EEM
area (185.6±40.3% vs. 112.0±12.1%, p=0.01). The representative
(n=3) Control Group (n=8) p-Value
.1 69.0±8.7 0.3
) 5 (63%) 0.9
4 (50%) 0.2
%) 8 (100%) 1.0
%) 8 (100%) 1.0
) 3 (38%) 0.9
) 5 (63%) 0.9
) 3 (38%) 0.9
%) 5 (63%) 0.2
.39 71.4±7.74 0.06
0.29 3.03±0.43 0.2
.8 22.1±7.8 0.9
0.0 12.5±4.3 <0.01
1.17 5.98±0.80 0.3
5.0 166.6±49.3 1.0
5.6 110.6±61.1 0.9
8.2 93.8±47.1 0.9
1.5 57.4±17.0 0.4
6.7 38.4±33.5 0.5
0.32 0.75±0.06 1.0
4.2 70.9±10.2 0.4
1.06 0.05±0.07 0.09
54 4975±1466 <0.01
44 3116±1406 0.01
22 1420±344 0.04
101±84 1.0
282 K. Yamanaga et al. / Journal of Cardiology 64 (2014) 279–284
Table 3
Intravascular ultrasound measurements at post-procedure and follow-up.
Post-procedure Follow-up
VLST Group (n=3) Control Group (n=8) p value VLST Group (n=3) Control Group (n=8) p-Value
Proximal region (1mm proximal to proximal edge of the stent)
EEM area (mm2) 12.5±3.3 15.5±6.5 0.5 21.2±3.9 16.6±4.6 0.2
Lumen area (mm2) 7.0±2.8 8.0±2.6 0.6 7.3±2.9 8.1±2.4 0.7
Minimum stent area site
EEM area (mm2) 10.5±4.5 11.8±5.0 0.5 15.9±2.6 13.3±4.8 0.5
Stent area (mm2) 4.9±1.7 6.1±2.3 0.3 5.0±1.8 6.3±2.3 0.2
Lumen area (mm2) N/A N/A 3.0±0.7 5.9±2.8 0.07
IH area (mm2) N/A N/A 2.2±1.5 0.6±0.4 0.03
Peri-stent P&M area (mm2) 5.6±2.9 5.7±2.8 0.7 10.8±2.7 7.0±3.4 0.04
Maximum EEM area site
EEM area (mm2) 13.6±4.5 17.0±4.9 0.4 24.2±7.3 18.8±4.4 0.1
Stent area (mm2) 6.5±2.4 7.6±2.6 0.4 6.5±5.2 7.9±2.6 0.4
Lumen area (mm2) N/A N/A 2.8±2.1 7.1±3.1 0.04
IH area (mm2) N/A N/A 3.7±5.2 2.3±3.2 0.2
Peri-stent P&M area (mm2) 7.1±2.1 9.4±3.4 0.3 17.8±2.7 10.8±3.2 0.03
Distal region (1mm distal to distal edge of the stent)
EEM area (mm2) 10.5±2.5 10.7±4.2 0.9 17.2±3.3 10.6±3.7 0.02
Lumen area (mm2) 6.3±1.8 6.4±2.4 0.9 6.8±1.3 6.3±3.0 0.8
Data are presented as mean±1SD.
VLST, very late stent thrombosis; EEM, external elastic membrane; IH, intimal hyperplasia; P&M, plaque and media; N/A, not available.
Table 4
Comparison of vessel responses between VLST and Control.
VLST Group (n=3) Control Group (n=8) p-Value
Proximal region (1mm proximal to proximal edge of the stent)
Vessel expansion (%) 173.4±34.2 111.7±23.0 0.04
Minimum stent area site
IH area (mm2) 2.2±1.5 0.6±0.4 0.03
EEM area (mm2) 5.3±5.5 1.4±3.2 0.07
Vessel expansion (%) 174.0±94.4 117.2±31.9 0.2
Peri-stent P&M area (mm2) 5.2±5.4 1.3±3.2 0.1
Peri-stent plaque expansion (%) 271.2±238.8 134.3±63.2 0.2
Maximum EEM area site
IH area (mm2) 3.7±5.2 2.3±3.2 0.2
EEM area (mm2) 10.6±3.4 1.7±1.9 0.01
Vessel expansion (%) 185.6±40.3 112.0±12.1 0.01
Peri-stent P&M area (mm2) 10.6±3.3 1.4±1.6 0.01
Peri-stent plaque expansion (%) 262.1±72.8 118.7±21.2 0.01
Distal region (1mm distal to distal edge of the stent)
Vessel expansion (%) 167.7±32.1 101.5±15.8 0.01
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oLST, very late stent thrombosis; IH, intimal hyperplasia.
xamples of serial IVUS images of a VLST case and control case are
hown in Figs. 1 and 2.
iscussion
The present study demonstrates that deﬁnite VLST occurred at
rate of 0.48%/patient and 0.39%/stent in our institution. Vascular
ositive remodeling occurred in the VLST group and anti-platelet
herapy discontinuation may be the cause of VLST.
pidemiology of VLST
VLST in SES occurs at a rate of 0.26–0.6%/y without attenuation
nd themortality of stent thrombosis is 11–45% (including deﬁnite,
ossible, and probable stent thrombosis) [2,9]. When a bare metal
tent (BMS) is implanted, endothelial coverageof stent strutsoccurs
nd it is the cause of restenosis. DES were created to solve this
roblem. Unfortunately, inﬂammation and hypercoagulable state
ccurred inDES-implanted segments by stent polymer anddrugs inreturn for the reduction in the restenosis rate. In this study, the fre-
quency of SES VLSTwas similar to that in previous studies [2,9], and
it did not decrease from year to year. It may be necessary to closely
follow SES-implanted patients, and to pay attention to medica-
tion adherence in these patients, especially regarding antiplatelet
therapy.
Pathogenic mechanism of SES VLST and clinical implications
Using intracoronary angioscopy, Higo et al. reported that yellow
color grade of neointimawithin SES-implanted segments increased
from baseline to follow-up compared with BMS. Thrombus was
detected in 25% of stent segments with yellow color grade of
neointima [10]. Histopathological analysis by Cook and colleagues
demonstrated that the thrombus of SES VLST showed signs of inﬁl-
trates with eosinophils. Eosinophilic inﬁltrates were associated
with evidence of vessel remodeling, presumably leading to sec-
ondary stent malapposition [11].
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Fig. 1. Representative example of angiographic and intravascular ultrasound images in very late stent thrombosis (VLST) patient. Sirolimus-eluting stent (SES;
3 on 30
t cedur
( : 16.0
i
V
p
d
a
t
t
i
s
s
F
i
P
e.0mm×18mm) had been implanted to LCX #13 on 25/6/2005. VLST occurred
ime of VLST. (A) Angiography on 18/1/2012 after 9 months of VLST. (B–D) Post-pro
E) Proximal edge. (F) Stent area. (G) Distal edge. External elastic membrane area: B
Although the frequency of myocardial infraction and mortal-
ty were not different between the patients with SES and BMS,
LST occurs far more frequently with DES than with BMS [12]. The
athogenesis of VLST between DES and BMS was also signiﬁcantly
ifferent [13]. All vasculature had not been positively remodeled
nd neointimal rupture was observed in all BMS VLST patients. On
he other hand, positive remodeling and incomplete stent apposi-
ion occurred in SES VLST.Our study also shows that vessel expansion was more frequent
n the VLST group not only at the stented segment but also at
tent edge. In case of the stent malapposition of SES or peri-stent
taining on follow-up IVUS or angiography, we may have to
ig. 2. Representative example of angiographic and intravascular ultrasound (IVUS) ima
mplanted to left anterior descending artery #6 on 14/10/2009. Routine follow-up angiog
ost-procedural stent implantation. (B) Proximal edge. (C) Stent area. (D) Distal edge. (E–G
lastic membrane area: B: 12.8mm2 C: 17.2mm2 D: 9.4mm2 E: 14.5mm2 F: 22.2mm2 G/3/2011. He had taken aspirin daily and not experienced effort angina until the
al stent implantation. (B) Proximal edge. (C) Stent area (D) Distal edge. (E–G) VLST.
mm2 C: 18.7mm2 D: 13.1mm2 E: 25.4mm2 F: 26.4mm2 G: 20.8mm2.
consider close follow-up and continuing dual antiplatelet therapy
for more than 1 year after SES implantation on the condition that
the blood pressure is kept under control and that the patient is not
at low risk for bleeding [14]. There are few reports analyzing serial
IVUS images post-procedural stent implant and at the time of VLST
in vivo. Our study showed that the vessel positive remodeling for
the period from stent placement to the time of VLST and/or late
stent malapposition is one of the most important morphological
causes of VLST by analyzing these serial IVUS images. In terms of
second-generation DES, several reports showed that neointimal
coverage increased more and uncovered struts decreased more
as compared with SES [15–17], and that vessel response against
ges in a control patient. Sirolimus-eluting stent (SES; 2.5mm×18mm) had been
raphy and IVUS had been done on 4/10/2010. (A) Angiography on 4/10/2010. (B–D)
) Follow up on 4/10/2010. (E) Proximal edge. (F) Stent area. (G) Distal edge. External
: 8.2mm2.
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uch second-generation DES has not been fully understood, and
ould require future research utilizing serial coronary imaging
evices.
tudy limitations
This was a small, non-randomized, retrospective, and cross-
ectional study performed at a single center. In our study, all eight
LST patients visited our hospital for chest pain and underwent
ngiography. Thus, probable or possible VLST based on ARC deﬁ-
ition was not included in our study and probably deﬁnite VLST
atients who did not visit our hospital were not included in our
tudy. In the VLST group, IVUS images were not taken by auto
ullback, and plaque volume was not analyzed. However, time-
onsuming auto pullback is not accepted ethically because VLST
s one of the most fatal complications after stent implantation.
VUS was taken after thrombectomy or angioplasty, and neoin-
ima could not be evaluated qualitatively, and could not be clearly
istinguished from thrombus. Furthermore, duration from index
rocedure to follow-up IVUS, which is considered to be associ-
ted with vascular response, was signiﬁcantly longer in the VLST
roup than in the control group, and might have affected our
esults.
onclusion
The positive vessel remodeling and late stent malapposition are
ome of the causes of SES VLST analyzed by serial IVUS images. The
ositive remodeling occurred not only in stented segments but also
t stent edges. In addition, discontinuation of antiplatelet therapy
ight cause VLST.
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